Company Profile for CardioVascular BioTherapeutics, Inc.The Business: CardioVascular cardiovascular /car·dio·vas·cu·lar/ (-vas´ku-ler) pertaining to the heart and blood vessels. car·di·o·vas·cu·lar adj. Abbr. BioTherapeutics, Inc. is a biopharmaceutical company focused on developing a new drug for the treatment of cardiovascular diseases Cardiovascular disease Disease that affects the heart and blood vessels. Mentioned in: Lipoproteins Test cardiovascular disease where the growth of new blood vessels Blood vessels Tubular channels for blood transport, of which there are three principal types: arteries, capillaries, and veins. Only the larger arteries and veins in the body bear distinct names. can improve the outcome for patients with these diseases. It's drug candidate, Cardio Cardio is the medical term used to reference the heart. From Greek kardia: heart. The Greek spelling using k is the reason for the usage of K in EKG (electrocardiogram). Vascu-Grow(TM), is designed to facilitate the growth of new blood vessels in the heart and other tissues with an impaired vascular vascular /vas·cu·lar/ (vas´ku-ler) 1. pertaining to vessels, particularly blood vessels. 2. indicative of a copious blood supply. vas·cu·lar adj. system.
Company: CardioVascular BioTherapeutics, Inc
Headquarters
Address: 1700 W. Horizon Ridge Parkway
Henderson, Nevada 89012
Main Telephone: 702-248-1174
Website: www.cvge.com
Ticker: CVBT(OTCBB)
Type of
Organization: Public
Investor Relations Agency
Industry: Health: Biotechnology
Key Executives: President: Daniel C Montano
Vice President/COO/Director: Thomas Stegmann M.S
Vice President/Director/CFO: Mickael A Flaa
Media Contact
Contact: Jodi Mack
Phone: (702) 248-1174
Email: pr@cvbt.com
|
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion